Work

Final analysis of SCORES, a phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.5554

Authors: Guangwen Yuan, Qingshui Li, Ge Lou, Judong Li, Mei Xu, Xiaowei Liu, Chen Yang, Jiajing Zhang, Shuguang Sun, Lingying Wu

Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Shandong Tumor Hospital, Third Affiliated Hospital of Harbin Medical University, Sun Yat-sen University Cancer Center, Xuzhou Central Hospital, Affiliated Hospital of Jining Medical University, Simcere Pharmaceutical (China)

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410812196

Cites:

Cited by:

Related to: 10